VIRIDIAN THERAPEUTICS, INC.

Viridian Therapeutics advances veligrotug for thyroid eye disease (TED) with positive phase 3 data, aiming for a 2025 BLA submission. VRDN-003 trials for TED are ongoing, with topline data expected in 2026. The company also progresses FcRn inhibitors VRDN-006 and VRDN-008, with significant clinical and preclinical updates anticipated in 2025. Viridian has a strong cash position to support these developments through 2027.

Viridian Therapeutics announces key 2025 priorities, including veligrotug's BLA submission for thyroid eye disease (TED) treatment, VRDN-003's phase 3 trials, and progress on FcRn inhibitors VRDN-006 and VRDN-008. Veligrotug shows promise as a best-in-class IV treatment for TED, with positive phase 3 results. VRDN-003, a subcutaneous option, is advancing with phase 3 trials. The company also highlights a strong cash position supporting operations into 2027.

Viridian Therapeutics reports positive Phase 3 data for veligrotug in thyroid eye disease (TED), aiming for a 2025 BLA submission. VRDN-003 trials are ongoing, with topline data expected in 2026. The company also progresses with FcRn inhibitors VRDN-006 and VRDN-008, anticipating clinical data in 2025. Viridian has a strong cash position, supporting operations into 2027.

Veligrotug shows promise in transforming TED care with positive phase 3 data. VRDN-003 trials are ongoing, with topline data expected in 2026. VRDN-006 IND submitted, with clinical data anticipated in 2025. VRDN-008 progressing in preclinical studies. Viridian has a strong cash position, supporting its portfolio through 2027.

Viridian Therapeutics announced positive Phase 3 THRIVE-2 trial results for veligrotug in chronic thyroid eye disease, showing significant efficacy in proptosis and diplopia with a favorable safety profile. Veligrotug met all primary and secondary endpoints, with a 56% proptosis responder rate and 32% diplopia resolution. BLA submission is planned for 2025, aiming to transform TED treatment. VRDN-003, a subcutaneous therapy, is also advancing with topline data expected in 2026.

Viridian Therapeutics to report THRIVE-2 phase 3 trial data on veligrotug for chronic thyroid eye disease on Dec 16, 2024. Conference call at 8:00 a.m. ET.

Viridian Therapeutics announced positive Phase 1/2 trial results for VRDN-001 in treating thyroid eye disease (TED), showing significant improvement in symptoms with a favorable safety profile. The global Phase 3 THRIVE program has been initiated, with promising data supporting VRDN-001 as a potential new treatment option for TED patients.